check_circleStudy Completed

Angina Pectoris, Postmenopause, Hormone Replacement Therapy

Bayer Identifier:
90832
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study to evaluate the effect of 1 mg Estradiol and 2 mg Drospirenone over 6 weeks on the coronary flow reserve of postmenopausal women with angina pectoris

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

N/A

Age

N/A

Trial summary

Enrollment Goal
60
Trial Dates
June 2002 - August 2003
Phase
Phase 2
Could I Receive a placebo
N/A
Products
Angeliq (E2/DRSP, BAY86-4891)
Accepts Healthy Volunteer
N/A

Primary Outcome

Secondary Outcome

Trial design

Double-blind, randomized, placebo-controlled, single center study to determine the effect of 1 mg estradiol and 2 mg drospirenone (1 tablet daily) over 6 weeks on the coronary flow reserve of post-menopausal women with angina pectoris measured by PET and echocardiography (ECHO)
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.